Navigation Links
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly form of brain cancer.

In pilot studies Cotara has shown encouraging results, demonstrating a 58% increase in the expected median survival time in a group of 28 patients suffering from recurrent late stage glioblastoma multiforme. This was considered a promising development in this serious and deadly disease, which kills half of its victims within 14 months of diagnosis.

Peregrine believes that combined positive data from this new study in India and ongoing U.S. glioblastoma trials would provide a foundation for advancing Cotara into Phase III trials.

"Cotara has demonstrated promising increases in survival in previous clinical studies of late stage glioblastoma patients, and we are optimistic that the very large population of glioblastoma patients served by our Indian study centers will facilitate timely enrollment in this important new trial," said Steven W. King, president and CEO of Peregrine. "We anticipate that positive data from this study, together with dosimetry and dosing data being collected in ongoing U.S. Cotara trials, will help us determine the optimal design of Phase III product registration trials."

This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study's primary objective is to confirm the maximum tolerated dose of Cotara in patients with GBM at first relapse.

Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patien ts alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), an NIH-developed technique that delivers the agent to the tumor with great precision, achieving up to a 10,000-fold greater concentration in local therapy exposure than conventional intravenous drug administration, while minimizing unwanted exposure to healthy tissue. This delivery method is expected to further enhance the tumor-killing efficacy of Cotara.

Mr. King continued, "We are launching this Cotara clinical program in India to take advantage of the large population of GBM patients served by our study centers and the high level of experience with CED delivery of the participating neurosurgeons, as well as the fact that the contract research organization overseeing the trial is highly experienced in conducting similar glioblastoma trials with many of the investigators involved with our study."

The new Cotara study is being conducted according to internationally accepted ICH GCP guidelines.


'"/>




Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
5. Top Pharmaceuticals Influence Doctors Prescriptions
6. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
7. Personalized Medicine and Innovative Pharmaceuticals
8. Pravastatin Launched by Watson Pharmaceuticals
9. Tata Industries picks up stake in Indigene Pharmaceuticals
10. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
11. OPPI Opposes Draft National Pharmaceuticals Policy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Northridge, CA (PRWEB) , ... March 24, 2017 ... ... Dr. Ramin Assili, announce that they are now offering treatments for sleep apnea ... treated at dental offices. Sleep apnea , specifically the obstructive type, is ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology: